PTHS PELTHOS THERAPEUTICS INC revenue, earnings and financials
For the quarter ended June 30, 2026, PELTHOS THERAPEUTICS INC reported revenue of $15.6M, net income of −$23.4M and diluted EPS of −$6.62; over the last four quarters revenue was $43.3M and net income −$86.4M; for the fiscal year ended December 2025 revenue was $16.8M.
PTHS annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $16.8M, gross profit n/a, operating income −$32.4M, net income −$43.3M (margin -257.9%), EPS −$23.04
- Fiscal year ended Dec 2024: revenue $0, gross profit n/a, operating income −$7.57M, net income −$7.96M (margin n/a), EPS −$14.27
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$6.86M, net income −$7.38M (margin n/a), EPS −$5.78
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$2.32M, net income −$2.46M (margin n/a), EPS n/a
PTHS quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $15.6M, net income −$23.4M, EPS −$6.62
- Quarter ended Mar 31, 2026: revenue $10.9M, net income −$25.1M, EPS −$7.57
- Quarter ended Dec 31, 2025 (from the annual report): revenue $9.39M, net income −$21.7M, EPS −$9.24
- Quarter ended Sep 30, 2025: revenue $7.41M, net income −$16.2M, EPS −$5.30
- Quarter ended Jun 30, 2025: revenue $0, net income −$3.45M, EPS −$5.29
- Quarter ended Mar 31, 2025: revenue $0, net income −$1.97M, EPS −$3.21
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$1.93M, EPS −$7.72
- Quarter ended Sep 30, 2024: revenue n/a, net income −$1.70M, EPS −$2.93
- Quarter ended Jun 30, 2024: revenue n/a, net income −$1.77M, EPS −$3.07
- Quarter ended Mar 31, 2024: revenue n/a, net income −$2.56M, EPS −$0.55
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$4.04M, EPS n/a
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.42M, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$953K, EPS n/a
- Quarter ended Mar 31, 2023: revenue n/a, net income −$967K, EPS n/a
PTHS cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$22.6M, share buybacks $0
- Fiscal year ended Dec 2024: operating cash flow −$5.79M, share buybacks $75.0K
- Fiscal year ended Dec 2023: operating cash flow −$981K, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$1.57M, share buybacks n/a
PTHS balance sheet
- Jun 30, 2026: cash $24.2M, total assets $137M, total liabilities $139M, shareholders' equity −$1.50M
- Mar 31, 2026: cash $32.0M, total assets $145M, total liabilities $126M, shareholders' equity $19.3M
- Dec 31, 2025: cash $18.0M, total assets $130M, total liabilities $91.5M, shareholders' equity $38.9M
- Sep 30, 2025: cash $14.2M, total assets $126M, total liabilities $68.2M, shareholders' equity $58.3M
- Jun 30, 2025: cash $59.0K, total assets $823K, total liabilities $7.32M, shareholders' equity −$6.50M
- Mar 31, 2025: cash $131K, total assets $911K, total liabilities $5.11M, shareholders' equity −$4.20M
- Dec 31, 2024: cash $513K, total assets $1.37M, total liabilities $4.08M, shareholders' equity −$2.71M
- Sep 30, 2024: cash n/a, total assets $2.14M, total liabilities $3.57M, shareholders' equity −$1.43M
What is PTHS's revenue?
PELTHOS THERAPEUTICS INC reported $43.3M of revenue over its last four quarters, through June 30, 2026.
Is PTHS profitable?
No. PELTHOS THERAPEUTICS INC lost $86.4M over the last four quarters.
What is PTHS's EPS?
Diluted earnings per share over the last four quarters were −$28.73; −$6.62 in the latest quarter.